LUMINA: Local Recurrence With Omission of Radiotherapy After Breast-Conserving Surgery in T1N0 Luminal A Breast Cancer

June 3-7, 2022; Chicago, Illinois
Women with clinically favorable low-risk breast cancer demonstrated a 5-year rate of local recurrence of less than 5% after breast-conserving survey and endocrine therapy without radiotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 116 KB
Released: June 15, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seagen & Genmab

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings